Company intelligence / Profile preview

Kronos Advisors

San Mateo, California, USAkronosca.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

The company shelved its last remaining clinical asset, istisociclib (a CDK9 inhibitor), after neurological adverse events in a phase 1/2 trial for ovarian cancer. Remaining assets are preclinical KAT inhibitors targeting multiple myeloma, HPV-driven cancers, and Sjögren’s disease. The company is divesting these assets following acquisition by Concentra Biosciences.

Therapeutic areas: ImmunologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Kronos Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kronos Advisors.

Explore the full profile